Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis
| Autor: | F Gay, S Oliva, M T Petrucci, V Montefusco, C Conticello, P Musto, L Catalano, A Evangelista, S Spada, P Campbell, R Ria, M Salvini, M Offidani, A M Carella, P Omedé, A M Liberati, R Troia, A M Cafro, A Malfitano, A P Falcone, T Caravita, F Patriarca, A Nagler, A Spencer, R Hajek, A Palumbo, M Boccadoro |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Melphalan Oral Adult medicine.medical_specialty Cancer Research medicine.medical_treatment Salvage therapy Administration Oral Aged Clinical Trials Phase III as Topic Humans Middle Aged Multiple Myeloma Salvage Therapy Thalidomide Transplantation Autologous Stem Cell Transplantation Hematology 03 medical and health sciences 0302 clinical medicine Anesthesiology and Pain Medicine Internal medicine medicine Clinical Trials Lenalidomide Multiple myeloma Chemotherapy Transplantation business.industry medicine.disease Surgery Phase III as Topic 030220 oncology & carcinogenesis Administration business Autologous 030215 immunology medicine.drug |
| Popis: | In newly diagnosed myeloma patients, upfront autologous transplant (ASCT) prolongs progression-free survival 1 (PFS1) compared with chemotherapy plus lenalidomide (CC+R). Salvage ASCT at first relapse may still effectively rescue patients who did not receive upfront ASCT. To evaluate the long-term benefit of upfront ASCT vs CC+R and the impact of salvage ASCT in patients who received upfront CC+R, we conducted a pooled analysis of 2 phase III trials (RV-MM-209 and EMN-441). Primary endpoints were PFS1, progression-free survival 2 (PFS2), overall survival (OS). A total of 268 patients were randomized to 2 courses of melphalan 200 mg/m2 and ASCT (MEL200-ASCT) and 261 to CC+R. Median follow-up was 46 months. MEL200-ASCT significantly improved PFS1 (median: 42 vs 24 months, HR 0.53; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|